Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer

MET amplification is rare in treatment-naïve metastatic colorectal cancer (CRC) tumors, but can emerge as a mechanism of resistance to anti-EGFR therapies. Preclinical and clinical data suggest that patients with MET amplified tumors benefit from MET-targeted therapy. Cabozantinib is an inhibitor of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jia, Jingquan, Morse, Michael A., Nagy, Rebecca J., Lanman, Richard B., Strickler, John H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121109/
https://www.ncbi.nlm.nih.gov/pubmed/30211110
http://dx.doi.org/10.3389/fonc.2018.00305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121109/
https://www.ncbi.nlm.nih.gov/pubmed/30211110
http://dx.doi.org/10.3389/fonc.2018.00305

Ejemplares similares